Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC

Reuters11-24

Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC

Shanghai Junshi Biosciences Co. Ltd. announced that its phase III clinical study evaluating JS001SC, a subcutaneous formulation of toripalimab, in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) has met its primary endpoints. The results demonstrated that the drug exposure of JS001SC was non-inferior to that of the existing toripalimab injection, with comparable efficacy and safety profiles. The company stated that detailed data from the study will be presented at an upcoming international academic conference. Shanghai Junshi Biosciences plans to communicate with regulatory authorities and submit a new drug application for JS001SC covering all approved indications of TUOYI® (toripalimab).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11926514), on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585571462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585571462","market":"us","top_or_hot":-1,"title":"Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> Co. Ltd. announced that its phase III clinical study evaluating JS001SC, a subcutaneous formulation of toripalimab, in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) has met its primary endpoints. The results demonstrated that the drug exposure of JS001SC was non-inferior to that of the existing toripalimab injection, with comparable efficacy and safety profiles. The company stated that detailed data from the study will be presented at an upcoming international academic conference. <a href=\"https://laohu8.com/S/688180\">Shanghai Junshi Biosciences</a> plans to communicate with regulatory authorities and submit a new drug application for JS001SC covering all approved indications of TUOYI® (toripalimab).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11926514), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJunshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 20:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SHJBF\">Shanghai Junshi Biosciences</a> Co. Ltd. announced that its phase III clinical study evaluating JS001SC, a subcutaneous formulation of toripalimab, in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) has met its primary endpoints. The results demonstrated that the drug exposure of JS001SC was non-inferior to that of the existing toripalimab injection, with comparable efficacy and safety profiles. The company stated that detailed data from the study will be presented at an upcoming international academic conference. <a href=\"https://laohu8.com/S/688180\">Shanghai Junshi Biosciences</a> plans to communicate with regulatory authorities and submit a new drug application for JS001SC covering all approved indications of TUOYI® (toripalimab).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11926514), on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL9gh6pf:1","article_id":"2585571462","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585571462","pubTimestamp":1763989124,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shanghai Junshi Biosciences Co. Ltd. announced that its phase III clinical study evaluating JS001SC, a subcutaneous formulation of toripalimab, in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer  has met its primary endpoints. The results demonstrated that the drug exposure of JS001SC was non-inferior to that of the existing toripalimab injection, with comparable efficacy and safety profiles. The company stated that detailed data from the study will be presented at an upcoming international academic conference. Shanghai Junshi Biosciences plans to communicate with regulatory authorities and submit a new drug application for JS001SC covering all approved indications of TUOYI .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688180":"君实生物","BK0239":"医药制造"},"translate_title":"君实生物报告特瑞普利单抗皮下注射治疗非小细胞肺癌III期成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9},"content_text":"Junshi Biosciences Reports Phase III Success for Subcutaneous Toripalimab in NSCLC\n    \n\nShanghai Junshi Biosciences Co. Ltd. announced that its phase III clinical study evaluating JS001SC, a subcutaneous formulation of toripalimab, in combination with chemotherapy for the first-line treatment of recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC) has met its primary endpoints. The results demonstrated that the drug exposure of JS001SC was non-inferior to that of the existing toripalimab injection, with comparable efficacy and safety profiles. The company stated that detailed data from the study will be presented at an upcoming international academic conference. Shanghai Junshi Biosciences plans to communicate with regulatory authorities and submit a new drug application for JS001SC covering all approved indications of TUOYI® (toripalimab).\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11926514), on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585571462","isCrawlerRequest":true}